Crystalline solvate forms of a pharmaceutical
The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions.
1. Crystalline solvate 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
2. The crystalline solvate of claim 1 , wherein the crystalline solvate is crystalline ethanolate 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
3. The crystalline solvate of claim 1 wherein the crystalline solvate is crystalline hydrate 17α-ethynylandrost -5-ene-3β,7β,17β-triol.
4. The crystalline solvate of claim 1 , wherein the crystalline solvate is crystalline methanolate 17α-ethynylandrost -5-ene-3β,7β,17β-triol.
5. A pharmaceutical composition comprising the crystalline solvate of claim 1 ; and one or more pharmaceutically acceptable excipients.
6. The pharmaceutical composition of claim 5 , wherein the crystalline solvate is crystalline ethanolate 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
7. The pharmaceutical composition of claim 6 , further comprising 1 CH 3 OH, 0.5 CH 3 OH, 1 H 2 O, 0.5 H 2 O or 2 H 2 O per 17β-ethynylandrost-5-ene-3β,7β,17β-triol.
8. The pharmaceutical composition of claim 5 , wherein the crystalline solvate is crystalline hydrate 17αethynylandrost -5-ene -3β,7β,17β-triol.
9. The pharmaceutical composition of claim 5 , wherein the crystalline solvate is crystalline methanolate 17α-ethynylandrost 5-ene-3β,7β,17β-triol.
10. The pharmaceutical composition of claim 5 , wherein the crystalline solvate is Form III 17αethynylandrost-5-ene-3β,7β,17β-triol.
11. The pharmaceutical composition of claim 5 , wherein the crystalline solvate is Form IV 17α-ethynylandrost-5-ene-3β,7β,17β-triol.
12. The pharmaceutical composition of claim 5 , wherein the crystalline solvate is Form V 17α-ethynylandrost -5-ene-3β,7β,17β-triol.
13. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.
14. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition contains less than about 2% by weight of impurities.
15. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.
16. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.
17. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.
18. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.
19. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.
20. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition contains less than about 3% by weight of impurities.